The Business Standard's Smart Investor (SI) reports focus on in-depth analysis and timely news concerning strategic investment trends, business deals, and financial manoeuvres within the corporate world.
The Business Standard's Smart Investor (SI) reports focus on in-depth analysis and timely news concerning strategic investment trends, business deals, and financial manoeuvres within the corporate world.
HDFC, ICICI Bank, L&T, HDFC Bank and BHEL are the top Sensex losers at this hour.
Idea Cellular, Bharti Airtel, Reliance Communication and Tata Communication are up 2-5% on the BSE.
The 30-share BSE Sensex opened 91 points higher at 20,301 levels and the 50-unit NSE Nifty was up 29 points in opening deals.
The early indicator, SGX Nifty was up by 40 points at 6,037 at 0825 hrs.
The 30-share Sensex was off 273 points at 20,176 and the 50-unit Nifty was down 89 points at 5995
The stock has dipped 3.6% to Rs 99.75 on reporting 23% yoy fall in standalone net profit at Rs 334 crore for Q3FY14.
Weakness in Asia and Europe dragged domestic benchmark share indices to their day's lows
The stock has rallied 6% to Rs 166 on reporting 42% yoy growth in consolidated net profit at Rs 92 crore for Q3FY14.
Meanwhile, auto and realty scrips buck trend;Mahindra & Mahindra, Tata Motors up 1%
IDBI Bank and four other shareholders which together hold a little over 45% shares are in the process of indentifying a buyer to exit from the company.
The stock has rallied 11% to Rs 359, with around 10% of total equity of the company changed hands on the BSE and NSE.
ONGC is down 1.6% at Rs 277.95 ahead of its Q3 earnings results while Sun Pharma is up 1.06% at Rs 617.50
The government approved a subsidy of Rs 3,333 per tonne for exports of raw sugar.
Since February, the stock has rallied 13.6% as compared to 0.73% rise in S&P BSE Sensex.
Titagarh Wagons, Texmaco Rail, Kalindee Rail, Kernex Microsystems and Hind Rectifiers are down 5-7% on BSE.
Drug major Cipla down by almost 6% due to dismal third quarter earnings performance
EBITDA margins for the quarter were down 660 basis points to 18% due to exposure to lower margin anti-retroviral segment, higher employee costs and other expenses.
The stock has rallied 11% to Rs 17 on back of heavy volumes after the government approved Rs 4,157 crore plan.
The board has recommended 300% or Rs 30 per share dividend for the year ended December 2013.
Markets are likely to open flat with stock specific action seen in early trades with focus on earnings